Passos-Bueno, M. R. (2001). A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.
Citación estilo ChicagoPassos-Bueno, Maria Rita. A Polymorphism in Endostatin, an Angiogenesis Inhibitor, Predisposes for the Development of Prostatic Adenocarcinoma. 2001.
Cita MLAPassos-Bueno, Maria Rita. A Polymorphism in Endostatin, an Angiogenesis Inhibitor, Predisposes for the Development of Prostatic Adenocarcinoma. 2001.
Precaución: Estas citas no son 100% exactas.